-transparent.png){kind=logo}
Lectin-like oxidized lipoprotein receptor-1 (LOX-1) is a specific receptor for atherogenic oxidized low density lipoprotein (OxLDL) which belongs to the scavenger receptor family. In the present report, we show that LOX-1 can also support cell adhesion to fibronectin (FN) in a divalent cation-independent fashion. CHO-K1 cells stably expressing bovine LOX-1 (BLOX-1-CHO), but not untransfected CHO-K1 cells, can adhere to FN-coated plates, but not to collagen-coated plates, in the presence of EDTA. BLOX-1-CHO adhesion to FN-coated plates can also be suppressed by scavenger receptor ligands, such as OxLDL, polyinosinic acid (poly I), and dextran sulfate, but not by native LDL, acetylated LDL, polycytidylic acid (poly C), or chondroitin sulfate. Cultured bovine aortic endothelial cells can similarly adhere to FN-coated plates, which was inhibited by OxLDL, poly I, and dextran sulfate in the presence of EDTA. LOX-1 may play an important role in cell adhesion to FN in an integrin-independent manner.
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
January 2001,
Trends in cardiovascular medicine,
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
September 2016,
Blood cells, molecules & diseases,
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
August 2016,
Biochemistry,
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
May 2007,
Current diabetes reviews,
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
December 2012,
Hypertension (Dallas, Tex. : 1979),
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
May 2024,
Journal of stomatology, oral and maxillofacial surgery,
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
January 2007,
Clinical and experimental rheumatology,
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
January 2009,
Current medicinal chemistry,
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
July 2013,
European journal of clinical investigation,
T Shimaoka, and
N Kume, and
M Minami, and
K Hayashida, and
T Sawamura, and
T Kita, and
S Yonehara
September 2008,
Cardiovascular & hematological disorders drug targets,
